Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
The return on assets (ROA) is N/A as of the fiscal period ended Wednesday, December 31, 2025.
Reported quarterly return on assets; no daily interpolation. Q4 FY2025 (2025-12-31): -16.45%.
RETURN ON ASSETS (ROA)
N/A
RETURN ON ASSETS (ROA) AVG TTM
-34.95%
RETURN ON ASSETS (ROA) AVG 3Y
-49.76%
RETURN ON ASSETS (ROA) AVG 5Y
-43.08%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Jyong Biotech Ltd. Ordinary Shares
Market Cap
$152.82M
Return on Assets (ROA)
N/A
TTM Avg
-34.95%
3Y Avg
-49.76%
5Y Avg
-43.08%
Market Cap
$154.79M
Return on Assets (ROA)
-35.50%
TTM Avg
-18.07%
3Y Avg
-62.20%
5Y Avg
-134.72%
Market Cap
$154.83M
Return on Assets (ROA)
-23.14%
TTM Avg
-29.29%
3Y Avg
-29.10%
5Y Avg
-28.90%
Market Cap
$150.43M
Return on Assets (ROA)
-127.14%
TTM Avg
-129.15%
3Y Avg
-91.50%
5Y Avg
-82.73%
Market Cap
$149.08M
Return on Assets (ROA)
-25.59%
TTM Avg
-36.78%
3Y Avg
-35.70%
5Y Avg
-27.05%
Market Cap
$148.62M
Return on Assets (ROA)
-20.01%
TTM Avg
-38.20%
3Y Avg
-34.64%
5Y Avg
-39.69%
Market Cap
$148.69M
Return on Assets (ROA)
-50.30%
TTM Avg
-131.74%
3Y Avg
-92.52%
5Y Avg
-67.08%
Market Cap
$148.48M
Return on Assets (ROA)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$148.36M
Return on Assets (ROA)
-76.12%
TTM Avg
-156.63%
3Y Avg
-142.29%
5Y Avg
-134.64%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Jyong Biotech Ltd. Ordinary Shares (MENS) | $152.82M | N/A | -34.95% | -49.76% | -43.08% |
| LifeMD, Inc. (LFMDP)vs › | $154.79M | -35.50% | -18.07% | -62.20% | -134.72% |
| Neuronetics, Inc. (STIM)vs › | $154.83M | -23.14% | -29.29% | -29.10% | -28.90% |
| Cardiol Therapeutics Inc. (CRDL)vs › | $150.43M | -127.14% | -129.15% | -91.50% | -82.73% |
| Codexis, Inc. (CDXS)vs › | $149.08M | -25.59% | -36.78% | -35.70% | -27.05% |
| Anavex Life Sciences Corp. (AVXL)vs › | $148.62M | -20.01% | -38.20% | -34.64% | -39.69% |
| ALX Oncology Holdings Inc. (ALXO)vs › | $148.69M | -50.30% | -131.74% | -92.52% | -67.08% |
| Veraxa Biotech Holding AG (VRXA)vs › | $148.48M | N/A | N/A | N/A | N/A |
| NervGen Pharma Corp. Common stock (NGEN)vs › | $148.36M | -76.12% | -156.63% | -142.29% | -134.64% |
| Voyager Therapeutics, Inc. (VYGR)vs › | $148.33M | -54.48% | -32.00% | -13.86% | -13.02% |
ROA
N/A
ROE
N/A
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -22.48% |
| 2024-12-31 | -47.42% |
| 2023-12-31 | -53.35% |
| 2022-12-31 | -75.81% |
| 2021-12-31 | -44.51% |
| 2020-12-31 | -14.92% |
